AstraZeneca
first new treatment in years potential first in class with robust efficacy plans include myositis | AstraZeneca
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
79 of 86
Related slides by other companies
ATAI
Investor Presentation
March 2023
phase proof of concept trial design all subjects tid tid placebo trial status in data anticipated randomized week study of and patients with | ATAI
ATAI
Investor Presentation
March 2023
changes in beta power from dose to hour post dose placebo low doses high doses no significant change significant increase preliminary data subject to change phase dose dependent frontal was demonstrated providing evidence of target engagement and mechanism of action a a | ATAI
MindMed
Investor Presentation
November 2024
for gad phase study designs voyage panorama | MindMed
ATAI
Investor Presentation
April 2023
phase proof of concept trial design all subjects tid tid placebo trial status in data anticipated randomized week study of and patients with | ATAI
Other recent decks by AstraZeneca
See all presentations (31 decks)
Results
February 2025
Results
November 2024
Results
November 2024
Investor Event
September 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights